CINGHIGH SIGNALFINANCIAL10-K

CING's financial position has deteriorated significantly with net losses increasing 44% to $22.4M, stockholders' equity plummeting 66% to just $2.5M, and current liabilities more than doubling.

The company is approaching financial distress with stockholders' equity falling to only $2.5M while current liabilities doubled to $10.3M, creating a severe liquidity mismatch. The dramatic increase in interest expense (170%) and total liabilities suggests the company has taken on substantial debt, likely out of funding necessity rather than strategic choice.

Comparing 2026-03-18 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

CING's financial position has deteriorated markedly across all key metrics, with net losses widening 44% to $22.4M while stockholders' equity collapsed 66% to just $2.5M. The company's leverage has increased substantially, evidenced by current liabilities doubling to $10.3M and interest expense surging 170% to $790K, while cash declined modestly to $11.0M. This financial profile suggests a biotech company burning through capital at an accelerating rate with diminishing equity cushion and increasing reliance on debt financing, raising serious questions about financial sustainability.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+170.2%
$292K→$790K

Interest expense surged 170.2% — significant debt increase or rising rates materially impacting earnings.

Current Liabilities
Balance Sheet
+107.4%
$5.0M→$10.3M

Current liabilities surged 107.4% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+69.6%
$7.4M→$12.6M

Liabilities grew 69.6% — significant increase in debt or obligations, assess impact on financial flexibility.

Stockholders Equity
Balance Sheet
-66.3%
$7.5M→$2.5M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Net Income
P&L
-44.4%
-$15.5M→-$22.4M

Net income declined 44.4% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-27.4%
-$15.6M→-$19.9M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Capital Expenditure
Cash Flow
-23.4%
$212K→$162K

Capex reduced 23.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-10.3%
$12.2M→$11.0M

Cash decreased 10.3% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-03-27
ADDED
We are targeting the ADHD treatment market, with an estimated US market size of approximately 100 million annual prescriptions of stimulants, as of September 2025.
Furthermore, the average branded long-acting stimulant wholesale acquisition cost (WAC) is $495/Rx.
It is reasonable to assume that a 1% market share capture would represent approximately $250 to $300 million in annual revenue less rebates and discounts in this marketplace.
Stimulants are historically the most commonly prescribed class of medications for ADHD and accounted for approximately 90% of all ADHD medication prescriptions in the United States during the year ended September 30, 2025.
For example, by contrast, non-stimulant medications are typically employed only in the second-line or adjunctive therapy setting.
+7 more — sign up free →
REMOVED
We are targeting the ADHD treatment market, with an estimated US market size of over $23 billion as of November 2023, of which $18.6 billion is attributable to stimulants.
Stimulants are historically the most commonly prescribed class of medications for ADHD and accounted for approximately 88% of all ADHD medication prescriptions in the United States for the 12-months ended November 2023.
By contrast, non-stimulant medications are typically employed only in the second-line or adjunctive therapy setting and accounted for approximately 12% of all ADHD medication prescriptions during that time.
Extended-release, or long-acting, dosage forms of stimulant medications are most frequently deployed as the first-line treatment for ADHD and constituted approximately $16 billion of the overall ADHD market spend and accounting for 54% of all stimulant prescriptions for the 12-months ended November 2023.
We believe there is a significant, unmet need within the current treatment paradigm for true once-daily ADHD stimulant medications with a duration that provides entire active-day coverage combined with an improved side effect profile to better serve the numerous unmet needs of patients.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →